{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:41:39Z","timestamp":1760035299906,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Urological cancers, including malignancies of the bladder, kidney, prostate, upper urinary tract, and penis, are among the most common cancers globally [...]<\/jats:p>","DOI":"10.3390\/ijms26136496","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:58:23Z","timestamp":1751878703000},"page":"6496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers, 2nd Edition"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4352-1784","authenticated-orcid":false,"given":"Vicen\u00e7","family":"Ruiz de Porras","sequence":"first","affiliation":[{"name":"GRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Badalona Applied Research Group in Oncology (B\u00b7ARGO), Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"},{"name":"CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.3390\/curroncol31110511","article-title":"The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers","volume":"31","author":"Antar","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: Status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Carrasco, R., Ingelmo-Torres, M., Trullas, R., Roldan, F.L., Rodriguez-Carunchio, L., Juez, L., Sureda, J., Alcaraz, A., Mengual, L., and Izquierdo, L. (2023). Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316578"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients with Urothelial Bladder Carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of Cell-free DNA Analysis to Cancer Treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Figols, M., Chekhun, S., Fernandez-Saorin, M., Perez-Criado, I., Bautista, A., Font, A., and Ruiz de Porras, V. (2025). Tumor-Educated Platelets in Urological Tumors: A Novel Biosource in Liquid Biopsy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083595"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","article-title":"RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics","volume":"28","author":"Best","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1158\/0008-5472.CAN-18-0887","article-title":"Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring","volume":"78","author":"Best","year":"2018","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1182\/blood-2011-03-344408","article-title":"Blood platelets contain tumor-derived RNA biomarkers","volume":"118","author":"Nilsson","year":"2011","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"155986","DOI":"10.1016\/j.prp.2025.155986","article-title":"Tumor-educated platelet, a potential liquid biopsy biosource in pancreatic cancer: A review","volume":"270","author":"Taheri","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103795","DOI":"10.1016\/j.critrevonc.2022.103795","article-title":"Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions","volume":"178","author":"Pardo","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Elahi Najafi, M.A., Yasui, M., Teramoto, Y., Tatenuma, T., Jiang, G., and Miyamoto, H. (2023). GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813733"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sundi, D., Collier, K.A., Yang, Y., Diaz, D.A., Pohar, K.S., Singer, E.A., Gupta, S., Carson, W.E., Clinton, S.K., and Li, Z. (2024). Roles of Androgen Receptor Signaling in Urothelial Carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16040746"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, P., Chen, J., and Miyamoto, H. (2017). Androgen Receptor Signaling in Bladder Cancer. Cancers, 9.","DOI":"10.3390\/cancers9020020"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vukovic, M., Chamlati, J.M., Hennenlotter, J., Todenhofer, T., Lutfrenk, T., Jersinovic, S., Tsaur, I., Stenzl, A., and Rausch, S. (2024). Interleukin-1beta\/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer-An Exploratory Analysis of Clinical and Tumor Biological Significance. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202401.0776.v1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Oxburgh, L. (2022). The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14174072"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mlynarczyk, G., Tokarzewicz, A., Gudowska-Sawczuk, M., Mroczko, B., Novak, V., Novak, A., Mitura, P., and Romanowicz, L. (2024). MMP-14 Exhibits Greater Expression, Content and Activity Compared to MMP-15 in Human Renal Carcinoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158107"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.21037\/tau-22-619","article-title":"Upregulation of matrix metalloproteinase 14 (MMP14) is associated with poor prognosis in renal clear cell carcinoma-a bioinformatics analysis","volume":"11","author":"Zhao","year":"2022","journal-title":"Transl. Androl. Urol."},{"key":"ref_23","first-page":"6605","article-title":"High expression of MMP14 is associated with progression and poor short-term prognosis in muscle-invasive bladder cancer","volume":"24","author":"Wang","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fahey, C.C., Nebhan, C.A., York, S., Davis, N.B., Hurley, P.J., Gordetsky, J.B., and Schaffer, K.R. (2023). Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216109"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","volume":"42","author":"Klumper","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2021.06.010","article-title":"The treatment landscape of metastatic prostate cancer","volume":"519","author":"Yamada","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Dhas, Y., Biswas, N., M, R.D., Jones, L.D., and Ashili, S. (2024). Repurposing metabolic regulators: Antidiabetic drugs as anticancer agents. Mol. Biomed., 5.","DOI":"10.1186\/s43556-024-00204-z"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Luconi, M., Cantini, G., and Crescioli, C. (2025). Repurposing glucose-lowering drugs for cancer therapy. Trends Cancer.","DOI":"10.1016\/j.trecan.2025.04.010"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11095-024-03811-1","article-title":"Repurposing of Metabolic Drugs Metformin and Simvastatin as an Emerging Class of Cancer Therapeutics","volume":"42","author":"Maurya","year":"2025","journal-title":"Pharm. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:05:15Z","timestamp":1760033115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":31,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136496"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136496","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,7,5]]}}}